AnneNoelNafzigerMDPhD

Addiction Medicine, Preventive Medicine, Clinical Pharmacology

Medical Director and Principal Investigator

Dr. Nafziger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1762 Central Avenue
Suite 201
Albany, NY 12205
Phone+1 518-650-2562

Fax+1 716-214-4460

Umea UniversityPhD, Epidemiology, 2002 - 2006
Johns Hopkins University School of Hygiene & Public HealthMHS, epidemiology, 1988 - 1990
Bassett Medical CenterResidency, Internal Medicine, 1985 - 1990
Bassett Medical CenterResidency, Internal Medicine, 1984 - 1987
Bassett Medical CenterInternship, Transitional Year, 1984 - 1985
Case Western Reserve University School of MedicineClass of 1984
Goshen CollegeBA, Biology, 1975 - 1979
Gallaudet Universitynone, deaf studies, 1977 - 1978

NY State Medical License 1987 - 2026
NJ State Medical License 2024 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Preventive Medicine Addiction Medicine
American Board of Clinical PharmacologyBoard Certification in Clinical Pharmacology

PubMed

6 citations
Inherent Dangers of Using Non-US Food and Drug Administration-Approved Substances of Abuse.
C Michael White, Thom Browne, Anne N. Nafziger
Journal of Clinical Pharmacology. 2021-08-15
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadows
Anne N. Nafziger, C Michael White
Journal of Clinical Pharmacology. 2021-08-15
1 citations
S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults
Lana Tran, Mina Nikanjam, Edmund V. Capparelli, Joseph S. Bertino, Anne N. Nafziger
European Journal of Clinical Pharmacology. 2021-03-23